What is the current Price Target for the Corvus Pharmaceuticals, Inc. stock?

The average Corvus Pharmaceuticals, Inc. target price is $32.64. This is 177.55% higher than the current stock price. The highest price target is 275.00%, the lowest is 131.89%. 9 Analysts have issued a price target Corvus Pharmaceuticals, Inc. 2027 .

How high will the Corvus Pharmaceuticals, Inc. stock rise?

No reliable answer can be given as to how high the Corvus Pharmaceuticals, Inc. stock will rise. The performance of stocks, including the Corvus Pharmaceuticals, Inc. stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Corvus Pharmaceuticals, Inc. stock today?

The performance of Corvus Pharmaceuticals, Inc. stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Corvus Pharmaceuticals, Inc. stock fall?

The decline in Corvus Pharmaceuticals, Inc. stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Corvus Pharmaceuticals, Inc. Forecast, price target & analysts

$11.79

0.26%

Nasdaq, Sep 30, 09:54 am EDT. Market open.

ISIN

US2210151005

Symbol

CRVS

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Analysts Charts Ownership News Strategies

Corvus Pharmaceuticals, Inc. Target price 2026 - Analyst rating & recommendation

Corvus Pharmaceuticals, Inc. Classifications & Recommendation

Buy

93%

Hold

Corvus Pharmaceuticals, Inc. Price Target

Target Price	$32.64
Price	$11.76
Potential	177.55% register free of charge
Number of Estimates	9

	9 Analysts have issued a price target Corvus Pharmaceuticals, Inc. 2027 . The average Corvus Pharmaceuticals, Inc. target price is $32.64. This is 177.55% register free of charge higher than the current stock price. The highest price target is $44.10 275.00% register free of charge , the lowest is $27.27 131.89% register free of charge .
	A rating was issued by 14 analysts: 13 Analysts recommend Corvus Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Corvus Pharmaceuticals, Inc. stock has an average upside potential 2027 of 177.55% register free of charge . Most analysts recommend the Corvus Pharmaceuticals, Inc. stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Annually

	Dec '25	2026 Estimates
Earnings Per Share $	-0.19	-0.77
	81.37%	305.26%
P/E		negative

10 Analysts have issued a Corvus Pharmaceuticals, Inc. forecast for earnings per share. The average Corvus Pharmaceuticals, Inc. EPS is

unlock

. This is

unlock

than earnings per share in the financial year 2025. The highest EPS forecast is

unlock

, the lowest is

unlock

This results in the following potential growth metrics and future valuations:

2025	$-0.19	81.37%
2026	$-0.77 305.26% unlock
2027	$-0.96 24.68% unlock
2028	$-0.81 15.63% unlock
2029	$-0.28 65.43% unlock
2030	$0.44 257.14% unlock
2031	$1.76 300.00% unlock
2032	$4.51 156.25% unlock
2033	$6.32 40.13% unlock

Current	-20.28	59.13%
2026	-15.34 24.34% unlock
2027	-12.28 19.95% unlock
2028	-14.59 18.81% unlock
2029	-41.93 187.39% unlock
2030	26.81 163.94% unlock
2031	6.66 75.16% unlock
2032	2.61 60.81% unlock
2033	1.86 28.74% unlock

Corvus Pharmaceuticals, Inc....

Current Corvus Pharmaceuticals, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
Goldman Sachs	Locked ➜ Locked	Locked	Apr 17 2026
Oppenheimer	Locked ➜ Locked	Locked	Mar 13 2026
Jefferies	Locked ➜ Locked	Locked	Jan 22 2026
Barclays	Locked ➜ Locked	Locked	Jan 21 2026
Oppenheimer	Locked ➜ Locked	Locked	Jan 21 2026
HC Wainwright & Co.	Locked ➜ Locked	Locked	Jan 20 2026
Barclays	Locked ➜ Locked	Locked	Oct 13 2025

Analyst Rating	Date
Locked Goldman Sachs: Locked ➜ Locked	Apr 17 2026
Locked Oppenheimer: Locked ➜ Locked	Mar 13 2026
Locked Jefferies: Locked ➜ Locked	Jan 22 2026
Locked Barclays: Locked ➜ Locked	Jan 21 2026
Locked Oppenheimer: Locked ➜ Locked	Jan 21 2026
Locked HC Wainwright & Co.: Locked ➜ Locked	Jan 20 2026
Locked Barclays: Locked ➜ Locked	Oct 13 2025

Discover more stocks with a high price target

NIO ADR 115.40%

Alibaba Group Holding Ltd 73.02%

Rheinmetall 69.93%

Tencent Holdings Ltd. 58.56%

Infineon 55.67%

Adyen 54.76%

BYD 51.95%

Uber Technologies 48.53%

TUI 47.22%

Siemens Energy 43.40%

Adidas 43.11%

Deutsche Telekom 41.02%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now